Trial Profile
A real world, multicenter, observational, ambispective study to evaluate efficacy and safety of Bevacizumab in patients with recurrent,platinum sensitive ovarian cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms VENUS
- 04 Jun 2019 Safety and efficacy results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 28 Jun 2017 New trial record
- 06 Jun 2017 Preliminary results (n=52) of retrospective cohort assessing efficacy and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.